David J Hall

Dr. David J Hall

Surgery, University of Wisconsin Health, Madison, Alabama, USA
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
DHDavid J Hall
David J Hall
EBErol V. Belli
Erol V. Belli
JGJon A. Gregg
Jon A. Gregg
JSJuan C. Salgado
Juan C. Salgado
MBMaher A. Baz
Maher A. Baz
TMTiago N. Machuca
Tiago N. Machuca

1 March 2019 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
DHDavid J Hall
David J Hall
EJEric I. Jeng
Eric I. Jeng
JGJon A. Gregg
Jon A. Gregg
APAndres Pelaez
Andres Pelaez
AEAmir M. Emtiazjoo
Amir M. Emtiazjoo
TMTiago N. Machuca
Tiago N. Machuca

1 September 2018 in Journal of Surgical Research
Verified
Journal Article
Closed access
KOKevin R. Olsen
Kevin R. Olsen
DHDavid J Hall
David J Hall
JMJuan C. Mira
Juan C. Mira
PUPatrick W. Underwood
Patrick W. Underwood
AAAjay B. Antony
Ajay B. Antony
GSGeorge A. Sarosi
George A. Sarosi

3 January 2013 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
DHDavid J Hall
David J Hall
JFJason Steven Fromm
Jason Steven Fromm
Drug reaction with eosinophilia and systemic symptoms syndrome is a potentially life-threatening hypersensitivity reaction with rash, fever, and internal organ involvement, often hepatitis, occurring most commonly two to eight weeks after initiation of a medication. The present case is an example of severe and potentially life-threatening hepatitis as a manifestation of drug reaction with eosinophilia and systemic symptoms syndrome.

19 July 2012 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
DHDavid J Hall
David J Hall
MBMaher Baz
Maher Baz
MDMichael J. Daniels
Michael J. Daniels
ESEdward Denmark Staples
Edward Denmark Staples
CKCharles T. Klodell
Charles T. Klodell
TBThomas M. Beaver
Thomas M. Beaver
Although lung transplantation is an accepted therapy for end-stage disease, recipient outcomes continue to be hindered by early primary graft dysfunction (PGD) as well as late rejection and bronchiolitis obliterans syndrome (BOS). We have previously shown that the pro-inflammatory cytokine response following transplantation correlates with the severity of PGD. We hypothesized that lung-transplant recipients with an increased inflammatory response immediately following surgery would also have a greater incidence of unfavorable long-term outcomes including rejection, BOS and ultimately death. A retrospective study of lung-transplant recipients (n = 19) for whom serial blood sampling of cytokines was performed for 24 h following transplantation between March 2002 and June 2003 at a single institution. Long-term follow-up was examined for rejection, BOS and survival. Thirteen single and six bilateral lung recipients were examined. Eleven (58%) developed BOS and eight (42%) did not. Subgroup analysis revealed an association between elevated IL-6 concentrations 4 h after reperfusion of the allograft and development of BOS (P = 0.068). The correlation between IL-6 and survival time was found to be significant (corr = −0.46, P = 0.047), indicating that higher IL-6 response had shorter survival following transplantation. An elevation in interleukin (IL)-6 concentration immediately following lung transplantation is associated with a trend towards development of bronchiolitis obliterans, rejection and significantly decreased survival time. Further studies are warranted to confirm the correlation between the immediate inflammatory response, PGD and BOS. Identification of patients at risk for BOS based on the cytokine response after surgery may allow for early intervention.

17 November 2022 in Surgery Open Science
Verified
Journal Article
Open access
GSGrigor S. Simitian
Grigor S. Simitian
DHDavid J Hall
David J Hall
GLGlen Leverson
Glen Leverson
ELEntela B. Lushaj
Entela B. Lushaj
ELErik E. Lewis
Erik E. Lewis
JMJames D Maloney
James D Maloney
Anastomotic leak (AL) after minimally invasive esophagectomy (MIE) is a well-described source of morbidity for patients undergoing surgical treatment of esophageal neoplasm. With improved early recognition and endoscopic management techniques, the long-term impact remains unclear. A retrospective review was conducted of patients who underwent MIE for esophageal neoplasm between January 2015 and June 2021 at a single institution. Cohorts were stratified by development of AL and subsequent management. Baseline demographics, perioperative data, and post-operative outcomes were examined. During this period, 172 MIEs were performed, with 35 of 172 (20.3%) complicated by an AL. Perioperative factors independently associated with AL were post-operative blood transfusion (leak rate 52.9% versus 16.8%; p = 0.0017), incompleteness of anastomotic rings (75.0% vs 19.1%; p = 0.027), and receiving neoadjuvant therapy (18.5% vs 30.8%; p < 0.0001). Inferior short-term outcomes associated with AL included number of esophageal dilations in the first post-operative year (1.40 vs 0.46, p = 0.0397), discharge disposition to a location other than home (22.9% vs 8.8%, p = 0.012), length of hospital stay (17.7 days vs 9.6 days; p = 0.002), and time until jejunostomy tube removal (134 days vs 79 days; p = 0.0023). There was no significant difference in overall survival between patients with or without an AL at 1 year (79% vs 83%) or 5 years (50% vs 47%) (overall log rank p = 0.758). In this large single-center series of MIEs, AL was associated with inferior short-term outcomes including hospital length of stay, discharge disposition other than to home, and need for additional endoscopic procedures, without an accompanying impact on 1-year or 5-year survival. In this large, single-center series of minimally invasive esophagectomies, anastomotic leak was associated with worse short-term outcomes including hospital length of stay, discharge disposition other than to home, and need for additional endoscopic procedures, but was not associated with worse long-term survival. The significant association between neoadjuvant therapy and decreased leak rates is difficult to interpret, given the potential for confounding factors, thus careful attention to modifiable pre- and peri-operative patient factors associated with anastomotic leak is warranted.